GALLIUM NITRATE FOR THE TREATMENT OF MALIGNANT TUMORS, A PHASE I STUDY
OBJECTIVES: I. Determine the safety and side effects of gallium nitrate (GAN) when used as
an anticancer agent in pediatric patients with refractory solid tumors, including malignant
brain tumors, neuroblastoma, rhabdomyosarcoma, and non-Hodgkin's lymphoma. II. Evaluate
these side effects in these patients.
OUTLINE: Single-Agent Chemotherapy. Gallium Nitrate, GAN, NSC-15200.
PROJECTED ACCRUAL: At least 3 patients will be accrued at each dose studied.
Primary Purpose: Treatment
Harry T. Whelan, MD
Medical College of Wisconsin
United States: Federal Government
|Marlene & Stewart Greenebaum Cancer Center, University of Maryland||Baltimore, Maryland 21201|
|Boston Floating Hospital Infants and Children||Boston, Massachusetts 02111|
|Medical College of Wisconsin||Milwaukee, Wisconsin 53226|